Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 4, Issue 137, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3004244
Keywords
-
Categories
Funding
- Imperial College Healthcare Trust Biomedical Research Centre
- Bill and Melinda Gates Foundation
- U.K. Medical Research Council
- Wellcome Trust
- Fondation Merrieux
- U.K. Biotechnology and Biological Sciences Research Council
- Swedish Medical Research Council
- COMBINE
- EU
- Karolinska Institutet Inflammation Consortium
- Millennium Foundation Singapore
- National Cancer Centre Singapore
- Nanyang Technical University
- Agence Nationale de la Recherche
- U.S. National Institutes of Health [R01AA020212]
- Tate + Lyle
- Procter and Gamble
- Ganeden
- Clasado
- Medical Research Council [G0801056B] Funding Source: researchfish
Ask authors/readers for more resources
The complex metabolic relationships between the host and its microbiota change throughout life and vary extensively between individuals, affecting disease risk factors and therapeutic responses through drug metabolism. Elucidating the biochemical mechanisms underlying this human supraorganism symbiosis is yielding new therapeutic insights to improve human health, treat disease, and potentially modify human disease risk factors. Therapeutic options include targeting drugs to microbial genes or co-regulated host pathways and modifying the gut microbiota through diet, probiotic and prebiotic interventions, bariatric surgery, fecal transplants, or ecological engineering. The age-associated co-development of the host and its microbiota provides a series of windows for therapeutic intervention from early life through old age.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available